Numeral Ltd is a Mauritius-based company. The Company is focused on the healthcare and biotechnology business as well as technological and commercial opportunities in the vertical. The Companyâ€™s subsidiaries include Numeral Financial Services Proprietary Limited and Numeral Biotechnologies Proprietary Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-04 Earnings release - Q1 2027

More about the company

Quotes

Date	Price	Change
26-07-22	US$0.0600	0.00%
26-07-21	US$0.0600	0.00%
26-07-20	US$0.0600	0.00%
26-07-17	US$0.0600	0.00%
26-07-16	US$0.0600	0.00%

End-of-day quote Mauritius S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Mauritius S.E. Other stock markets 2026-07-22			5-day change	1st Jan Change
0.0600 ^USD	0.00%		0.00%	-40.00%

07-16	Numeral Limited Reports Earnings Results for the Full Year Ended February 28, 2026	CI
06-29	Numeral Ltd Announces Appointment of Kevin Evans as Independent Non-Executive Director, Effective July 1, 2026	CI

Market Cap	7.46M 6.53M 6.06M 5.57M 10.5M 719M 10.65M 72.24M 28.27M 352M 27.99M 27.38M 1.22B	P/E 2025	7.36x	P/E 2026	140x
Enterprise Value	11.34M 9.94M 9.23M 8.48M 15.98M 1.09B 16.21M 110M 43.02M 536M 42.58M 41.66M 1.85B	EV / Sales 2025	7,730,075x	EV / Sales 2026	6,850,543x
Free-Float	99%	Yield 2025 *	-	Yield 2026	-

07-16	Numeral Limited Reports Earnings Results for the Full Year Ended February 28, 2026	CI
06-29	Numeral Ltd Announces Appointment of Kevin Evans as Independent Non-Executive Director, Effective July 1, 2026	CI
06-01	Numeral Ltd Delays Earnings Results Release	CI
01-21	Numeral Limited Reports Earnings Results for the Nine Months Ended November 30, 2025	CI
25-10-17	Numeral Limited Reports Earnings Results for the Half Year Ended August 31, 2025	CI
25-10-01	Numeral Ltd. Appoints Mr. Jacobus Botma as an Executive Director, Effective September 29, 2025	CI
25-07-16	Numeral Limited Reports Earnings Results for the First Quarter Ended May 31, 2025	CI
25-07-16	Numeral Limited Announces Resignation of Glenn Henning as Director	CI
25-07-01	Numeral Limited Reports Earnings Results for the Full Year Ended February 28, 2025	CI
25-03-18	Numeral Limited Appoints Glenn Henning as Non-Executive Director	CI
25-01-17	Numeral Limited Reports Earnings Results for the Nine Months Ended November 30, 2024	CI
24-12-01	Numeral Limited (MUSE:GOLI.N0000) signed terms to acquire 51% stake in Longevity.	CI
24-10-14	Numeral Limited Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2024	CI

12-19	Numeral : SEM Communique	PU
25-07-24	Numeral : Notice of shareholder meeting	PU
24-07-08	Numeral : Notice of shareholder meeting	PU
23-05-10	Go Life International : SEM Communique	PU
22-07-26	Go Life International : Communique	PU

Numeral Limited Stock

Stocks

NXII.N0000

MU0810N00005

Biotechnology & Medical Research

Valuation: Numeral Limited

Chart: Numeral Limited

Latest news : Numeral Limited

Press Releases: Numeral Limited

Quotes and Performance

Course Extremes

Managers and Directors: Numeral Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 month	-33.33%
3 months	-33.33%
6 months	-40.00%
Current year	-40.00%

1 week	0.06	0.06
1 month	0.06	0.09
Current year	0.06	0.1
1 year	0.06	0.1
3 years	0.06	0.1
5 years	0.06	0.1
10 years	0.06	0.4

Director	Title	Age	Since
Mohamed Yusuf Sooklall CHM	Chairman	67	2011-07-03
David van Niekerk BRD	Director/Board Member	53	2023-10-26
Neville Graham BRD	Director/Board Member	-	2023-10-26

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUMERAL LIMITED	0.00%	0.00%	-40.00%	-40.00%	7.46M
LONZA GROUP AG	+0.88%	-6.12%	-5.36%	+11.23%	46.06B
REVOLUTION MEDICINES, INC.	-0.14%	-0.76%	+378.26%	+583.71%	38.91B
BEONE MEDICINES AG	+0.39%	+2.79%	+8.23%	+61.99%	35.57B
IQVIA HOLDINGS INC.	-1.54%	-4.01%	+5.95%	-13.03%	33.13B
CELLTRION, INC.	-0.87%	-3.19%	-1.27%	+29.16%	26.42B
ASCENDIS PHARMA A/S	-1.28%	-6.20%	-	-	16.61B
MEDPACE HOLDINGS, INC.	-0.67%	-0.21%	+10.55%	+115.31%	15.08B
EUROFINS SCIENTIFIC SE	-5.95%	-4.49%	+4.77%	+8.46%	14.08B
ICON PUBLIC LIMITED COMPANY	+0.40%	-2.79%	+3.58%	-31.98%	12.81B
Average	-0.88%	-2.03%	+40.52%	+80.54%	23.87B
Weighted average by Cap.	-0.57%	-2.60%	+68.45%	+122.58%

	2025	2026
Net sales	1.69 1.48 1.38 1.27 2.38 163.32 2.42 16.4 6.42 79.92 6.35 6.22 276.07	2.2 1.93 1.79 1.64 3.1 212.28 3.14 21.32 8.34 103.87 8.26 8.08 358.83
Net income	169K 148K 137K 126K 238K 16.29M 241K 1.64M 640K 7.97M 634K 620K 27.53M	79.94K 70.04K 65.02K 59.75K 113K 7.71M 114K 775K 303K 3.77M 300K 294K 13.04M
Net Debt	3.76M 3.29M 3.06M 2.81M 5.29M 363M 5.37M 36.42M 14.26M 177M 14.11M 13.81M 613M	3.89M 3.41M 3.16M 2.91M 5.48M 375M 5.56M 37.68M 14.75M 184M 14.6M 14.28M 634M